Ultimately, the nation’s business interests are put before safety. Vaccines generate US$25 billion in annual sales. At any one time, the Center for Disease Control and Prevention has 271 new vaccines under development.
With this sum of money at stake, it is in the national economic interest to approve as many vaccines for sale as possible. In an environment where companies put profits ahead of patient safety, this leads to unsafe vaccinations reaching the market.
There are examples of pharmaceutical companies manipulating testing to get their products to market early. Stephen A. Krahling and Joan A. Wlochowski, two former Merk virologists, came forward and alleged that the firm faked efficacy tests for its measles, mumps and rubella (MMR) vaccine.